Bausch + Lomb Corporation (NYSE: BLCO) announced positive 24-month results from a pivotal U.S. clinical trial of its ELIOS System for treating elevated intraocular pressure in patients with open angle glaucoma.

The prospective, multicenter study enrolled 318 patients with mild to moderate primary open-angle glaucoma and cataracts at 20 U.S. sites. The trial met both primary effectiveness endpoints, demonstrating statistically significant intraocular pressure reduction.

Key results showed 76% of patients achieved a 20% or greater reduction in unmedicated diurnal intraocular pressure, with patients experiencing an average 7.4 mmHg decrease. Additionally, 82% of patients were medication-free at 23 months. The study reported no intraoperative complications during the ELIOS procedure and a postoperative adverse event rate similar to cataract surgery alone.

The ELIOS procedure uses excimer laser technology to create microchannels in the trabecular meshwork without requiring implants. The system is currently CE marked in Europe and under development in the United States, where it has not been reviewed by the FDA for safety and efficacy.

"These strong U.S. study results reinforce everything we've learned about ELIOS during the years it has been available in Europe," said Yehia Hashad, executive vice president of R&D and chief medical officer at Bausch + Lomb.

The company plans to submit detailed trial results to a future medical meeting and peer-reviewed journal. In Europe, ELIOS has been available for several years with data from 12 clinical studies covering more than 850 treated eyes.

The information is based on a company press release statement.